Company intelligence / Profile preview

Safe

Ownership: Public · SGBX
Development stage: Commercial

Overview

The platform enables high-performance diagnostic evaluations for early identification of potential adverse drug reactions. It is designed to improve patient outcomes by reducing ADRs without increasing healthcare costs. The system has been developed with input from clinicians and patients, focusing on usability and up-to-date information curation. No traditional clinical trial pipeline; instead, it is a digital health tool deployed in real-world settings. No published clinical trial results referenced.

Therapeutic areas: Other
Modalities: Non-pharmacological therapy
Industry: Digital Health Medical Devices

Financials

Market cap: $533.7K
Total revenue: $2.1M
Enterprise value: $23.6M

Beyond the preview

Go deeper on Safe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Safe.

Explore the full profile